Ozempic and related drugs may do more than curb appetite and control blood sugar—they now appear linked to lower risks of depression and anxiety.

A large long-term study followed nearly 100,000 people for more than a decade and found that GLP-1 drugs such as semaglutide were associated with fewer psychiatric hospital visits and fewer sick days, according to the research summary. That finding pushes these medicines into a broader conversation about health, one that stretches beyond diabetes treatment and headline-grabbing weight loss results.

The new signal suggests GLP-1 drugs may touch mental health outcomes as well as metabolism.

The result matters because Ozempic and Wegovy already sit at the center of a major medical and cultural shift. Doctors prescribe them for diabetes and weight management, while patients and health systems watch their wider effects closely. If the reported mental health benefits hold up under further scrutiny, they could reshape how clinicians think about the full impact of these medications.

Key Facts

  • Researchers tracked nearly 100,000 people over more than 10 years.
  • The study linked GLP-1 drugs, including semaglutide, to lower depression and anxiety risk.
  • Reports indicate fewer psychiatric hospital visits among people taking the drugs.
  • Sources suggest users also recorded fewer sick days.

The study does not automatically prove that the drugs directly prevent mental illness, and that distinction will matter as researchers dig deeper. Other factors could help explain the pattern, and future work will need to test cause and effect more directly. Even so, the scale and duration of the data give the findings weight at a moment when demand for GLP-1 treatments keeps rising.

What happens next will likely shape both prescribing decisions and public expectations. Researchers will look for confirmation, regulators and clinicians will watch for stronger evidence, and patients will ask whether these medicines offer benefits beyond the scale. If this signal holds, GLP-1 drugs could become part of a much bigger story about how metabolic treatments influence mental health.